Nick,
as far as the large OS# and float I am well documented here as to what I think of it. With FDA clearnace for 2 trials, new financing, several patents PR'd and a huge news blitz for several months we sit around 15 cents per share. While many here think the OS# isn't a big deal, I disagree. If the last 3+ months didn't prove that, nothing will I guess.
What will it take? Here are just a few, the NDA approval is years away so I hope ACT is one of the 15% that make it..
1)Initiate trials
2)Treat a patient
3)Have positive safety results as all of the upcoming trials will be using MA09-hRpe so it is vital to moving forward.
4)Have substantial efficacy results over time.
5)New CEO and BOD's
6)Restructure the shares(for me I hope we try a big board exchange)
7)Quit the massive dilution
8)Pay any and all debts instead of waiting years and having fairness hearings
9)No more GIFTED shares until something is truly accomplished.
10)Some or all of the above will give this company credibility which it sorely has lacked the past 10 years and imo ACT brought that on.
